# GASTROINTESTINAL BLEEDING

## 定義

• Intraluminal blood loss anywhere from the oropharynx to the anus

• Classification: **upper** = above the ligament of Treitz; **lower** = below the ligament of Treitz

• “Severe” GIB: defined as having associated shock, orthostatic hypotension, ↓ Hct by 6% (or ↓ Hb by 2 g/dL), or requiring transfusion ≥2U PRBCs. Requires hospitalization.

## 臨床表現

• **Hematemesis** = blood in vomitus (UGIB)

• **Coffee-ground emesis** = emesis of blood exposed to gastric acid (UGIB)

• **Melena** = black, tarry stools from digested blood (usually UGIB, but can be from R colon)

• **Hematochezia** = bloody or maroon-colored stools (LGIB or rapid UGIB)

## Initial management

• **Assess severity:** _VS including orthostatic_ Δ_s, JVP._ Tachycardia (can be masked by βB use) suggests 10% volume loss, orthostatic hypotension 20% loss, shock >30% loss. Scoring systems predict rebleeding & mortality: AIMS65 & Glasgow-Blatchford.

• **History:** prior GIB, tempo of current bleed, specific bleeding 表現 (see above), other GI signs and symptoms (eg, abd pain, Δ in bowel habits, weight loss, N/V), NSAID/ASA or EtOH use, anticoag/antiplt drugs, h/o or risk factors for cirrhosis, radiation, prior GI or aortic surgery

• **Physical exam:** localizable abd tenderness, peritoneal signs, masses, LAN, prior surgery,

signs of liver disease (hepatosplenomegaly, ascites, jaundice, telangiectasias), rectal exam: masses, hemorrhoids, anal fissures, stool appearance, color

• **Resuscitation:** placement of 2 large-bore (18-gauge or larger) intravenous lines Volume replacement: NS or LR to achieve normal VS, UOP, & mental status

• **Lab studies: Hct** (_may be normal_ in first 24 h of acute GIB before equilibration)

2–3% → 500 mL blood loss; low MCV → Fe deficient and chronic blood loss; **plt**, **PT**, **PTT;** BUN/Cr (ratio >36 in UGIB b/c GI resorption of blood ± prerenal azotemia); LFTs

• **Transfuse:** type & cross; use O-neg if emerg; for UGIB (esp. with portal HTN) transfuse with more restrictive Hb goal (eg, 7 g/dL) or >8 g/dL if CAD (_JAMA_ 2016;316:2025)

• **Reverse coagulopathy:** consider FFP to normalize PT; plts to keep count >50,000

• **Triage:** alert endoscopist. Consider ICU if unstable VS or poor end organ perfusion.

Intubation for: emergent EGD, ongoing hematemesis, shock, poor resp status, Δ MS

? OutPt management if SBP ≥110, HR <100, Hb ≥13 (♂) or ≥12 (♀), BUN <18, ∅ melena, syncope, heart failure, liver disease (_Clin Gastro Hepatol_ 2015;13:115)

## Diagnostic studies

• UGIB: **EGD** within 24 h. If severe bleed, ↑ Dx/Rx yield by gastric lavage and **erythro 250 mg IV 30 min prior to endoscopy** to clear stomach contents (_Am J Gastro_ 2006;101:1211).

• LGIB: **colonoscopy** (identifies cause in >70%); if severe, colo within 12 h → consider rapid purge with PEG solution (6–8 L over 4–6 h). If hematochezia a/w orthostasis, concern for brisk UGIB → _exclude UGIB with EGD first._ Push enteroscopy, anoscopy, capsule endoscopy in combo with urgent colo results in dx >95% of cases (_GI Endo_ 2015;81:889).

• Imaging: if too unstable for endo or recurrent bleeding, can then → IR procedure or surgery

**tagged RBC scan:** can identify general luminal location if bleeding rate ≥0.04 mL/min

**CT angiography:** faster to obtain than RBC scan, detects bleeding ≥0.3 mL/min

**arteriography:** can localize exact vessel if bleeding rates ≥0.5 mL/min, _allows for IR Rx_

• Emergent exploratory laparotomy (last resort) if no localization and life-threatening bleed

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="2"><p>Etiology UGIB</p></td><td><p>Comment &amp; 治療</p></td></tr><tr><td colspan="2"><p><b>PUD</b> (20–67%)</p><p>(<span><i>Am J Gastro</i> 2014;109:1005; <span><i>NEJM</i></span> 2016;374:2367; <span><i>Br J Clin Pharm</i></span> 2017;83:1619</span>)</p><p>See “PUD”</p></td><td><p><i>治療:</i> <b>PPI:</b> 40 mg PO or IV BID. ? Octreotide if suspect varices.</p><p><b>Endoscopic therapy:</b> epi inj + bipolar cautery or hemoclip. Bx for ? <i>H. pylori</i> and treat if ⊕.</p><p><i>High-risk (for rebleeding) ulcer</i>: arterial spurting, adherent clot, visible vessel. Endo Rx, IV PPI × 72 h post EGD, then Δ to high-dose oral PPI. If fail, arteriography with embolization; surgery (last resort).</p><p><i>Intermediate-risk ulcer</i>: oozing, in otherwise stable Pt. Endo Rx, can Δ to oral PPI after EGD and observe 24–48 h.</p><p><i>Low-risk ulcer:</i> clean-based or flat. Oral PPI &amp; ? discharge.</p><p>Hold anticoag &amp; antiplatelet Rx until hemostasis; can resume after hemostasis &amp; PPI on board (<span><i>Endoscopy</i> 2015;47:a1</span>)</p></td></tr><tr><td colspan="2"><p><b>Erosive gastropathy</b></p><p>(4–31%)</p></td><td><p>Precipitants: NSAIDs, ASA, EtOH, cocaine, gut ischemia, XRT</p><p>Stress-related mucosal injury in ICU 病人. Risk factors include severe coagulopathy, mech vent &gt;48 h, high-dose glucocorticoids</p><p>治療: high-dose PPI</p></td></tr><tr><td colspan="2"><p><b>Erosive esopha-gitis</b> (5–18%)</p></td><td><p>Risk factors: cirrhosis, anticoagulation, critical illness. Rx offending cause + high-dose PPI; repeat EGD later to 排除 underling Barrett’s.</p></td></tr><tr><td colspan="2"><a id="page_3-4"></a><p><b>Esophageal or gastric varices</b> (4–20%)</p><p>(<span><i>Clin Gastro Hepatol</i> 2015;13:2109; <span><i>J Gastro Hepatol</i></span> 2016;31:1519; <span><i>Hep</i></span> 2017;65:310</span>)</p><p>See “Cirrhosis”</p></td><td><p>2° to portal HTN. If isolated gastric → 排除 splenic vein thrombosis.</p><p><i><span>Pharmacologic</span></i></p><p>Start <b>octreotide</b> pending EGD if suspect varices: 50 µg IVB → 50 µg/h (84% success). Rx for 2–5 d, but most benefit within 24–48 h.</p><p>抗生素: 20% cirrhotics 表現為 GIB have infxn, &amp; ~50% develop infxn during hospitalization; Ppx with IV CTX, cipro, or levoflox × 7 d</p><p><i><span>Nonpharmacologic</span></i></p><p>Esophageal varices: <b>endoscopic band ligation</b> (&gt;90% success). Covered esophageal stent placement or balloon tamponade if refractory as bridge to TIPS (consider early espec. if Child-Pugh C).</p><p>Gastric varices: arteriography with coiling, or if available, endoscopic injection of cyanoacrylate (glue). If refractory: TIPS or balloon-retrograde transvenous obliteration.</p></td></tr><tr><td colspan="2"><p>Portal HTN gastropathy</p></td><td><p>↑ portal venous pressure → ectatic vessels, hyperemia in prox. gastric body. No endoscopic option; Rx portal HTN (octreotide), βB.</p></td></tr><tr><td rowspan="4"><p><b>Vascular (2–8%)</b></p></td><td><p>Angioectasia AVMs, HHT (see below)</p></td><td><p>AVMs congenital. Angioectasia (ectatic submucosal vessels) a/w ↑ age, CKD, cirrhosis, CTD, severe CV dis. <i>Heyde syndrome:</i> GIB due to angioectasias + aortic stenosis. Endo Rx.</p></td></tr><tr><td><p>Dieulafoy’s lesion</p></td><td><p>Large (1–3 mm) submucosal artery protruding through fundal mucosa → sudden, massive UGIB. <i>Difficult to identify.</i> Endo Rx.</p></td></tr><tr><td><p>Gastric antral vasc. ectasia (GAVE)</p></td><td><p>“<i>Watermelon stomach</i>”; ectatic gastric vessels, often a/w cirrhosis, CTD, typically older ♂. Rx with EGD with thermal hemostasis, repeat q4–8wk to eradicate lesions. TIPS does <i>not</i> improve outcomes.</p></td></tr><tr><td><p>Aortoenteric fistula</p></td><td><p>AAA or aortic graft erodes into 3<sup>rd</sup> portion of duodenum. 表現為 “herald bleed”; if suspected, diagnose by endoscopy or CT.</p></td></tr><tr><td colspan="2"><p>Malignancy (2–8%)</p></td><td><p>Endoscopic hemostasis of mass temporizing measure till cancer Rx</p></td></tr><tr><td colspan="2"><p>Mallory-Weiss tear (4–12%)</p></td><td><p>GE jxn lacerations due to vomiting → ↑ intraabd pressure &amp; shearing effect. Can self-resolve without endo Rx. Rx with antiemetics, PPI.</p></td></tr><tr><td colspan="2"><p>Cameron’s lesions</p></td><td><p>Linear erosions in hiatal hernia due to mech trauma of diaphragm</p></td></tr><tr><td colspan="2"><p>Post-sphincter-otomy bleeding</p></td><td><p>Occurs in ~2% of ERCP with sphincterotomy; ↑ risk with more complic. procedure. Bleeding into duodenum. Rx with endo hemostasis.</p></td></tr></tbody></table>

(_GI Endosc Clin N Am_ 2015;25:415)

<table><colgroup><col> <col></colgroup><tbody><tr><td><p>Etiology LGIB</p></td><td><p>Comment &amp; 治療 <span>(<i>NEJM</i> 2017;376:1054)</span></p></td></tr><tr><td><p><b>Diverticular bleed</b> (30%)</p></td><td><p><i>病生理:</i> Intimal thickening and medial thinning of vasa recta as they course over dome of diverticulum → weakening of vascular wall → arterial rupture. Diverticula more common in left colon; but <i>bleeding diverticula more often in right colon.</i></p><p><i>Clinical:</i> older, ASA/NSAIDs, usually painless hematochezia ± abd cramping</p><p><i>治療:</i> Usually stops spont. (~75%) but may take hrs–days; ~20% recur. Can perform endo hemostasis with epi injections ± electrocautery, hemoclip, banding. Intra-arterial vasopressin or embo. Surgery (partial colectomy) last resort.</p></td></tr><tr><td><p>Polyp/Tumor (20%)</p></td><td><p>Typically slow ooze, 表現為 fatigue, weight loss, iron deficiency anemia</p></td></tr><tr><td><p>Colitis (20%)</p></td><td><p>Infectious (see “Acute Diarrhea”), IBD, ischemic colitis, XRT</p></td></tr><tr><td><p>Anorectal disorders (20%)</p></td><td><p>Internal, external hemorrhoids; anal fissures, rectal ulcers, rectal varices (Rx by ↓ portal venous pressure in cirrhotics), XRT</p></td></tr><tr><td><p>Vascular (&lt;10%)</p></td><td><p>Angioectasia &amp; AVMs (see above). <i>Hereditary hemorrhagic</i></p><p><i>telangiectasia (Weber-Osler-Rendu):</i> diffuse AVMs, telangiectasias</p><p>throughout GI mucosa (also involve lips, oral mucosa, fingertips).</p></td></tr><tr><td><p>Meckel’s diverticulum</p></td><td><p>Congenital blind intestinal pouch due to incomplete obliteration of vitelline duct. <span>2</span>% of pop, within <span>2′</span> of IC valve, <span>2″</span> long, ♂:♀ <span>2</span>:1, often present age 2 y (but can cause obscure GIB in adults). Dx with <sup>99m</sup>Tc-pertechnetate scintigraphy. Rx with angioembo, surgical resection.</p></td></tr></tbody></table>

## Obscure GIB (_Am J Gastro_ 2015;110:1265; _Gastro_ 2017;152:497)

• **定義:** continued bleeding (melena, hematochezia) despite ⊖ EGD & colo; 5% of GIB

• **原因:** Dieulafoy’s lesion, GAVE, small bowel angiodysplasia, ulcer or cancer, Crohn’s disease, aortoenteric fistula, Meckel’s diverticulum, hemobilia

• **Diagnosis:** repeat EGD with push enteroscopy/colonoscopy when bleeding is active

If ⊖, video capsule to evaluate small intestine (_GIE_ 2015;81:889)

If still ⊖, consider 99mTc-pertechnetate scan (“Meckel’s scan”), enteroscopy (single-balloon, double-balloon or spiral), tagged RBC scan and arteriography
